Development of Novel-nanobody-based Lateral-flow Immunochromatographic Strip Test for Rapid Detection of Recombinant Human Interferon α2b

Overview

Journal J Pharm Anal

Specialty Chemistry

Date 2022 May 18

PMID 35582401

Authors

Xi Qin

Maoqin Duan

Dening Pei

Jian Lin

Lan Wang

Peng Zhou

Wenrong Yao

Ying Guo

Xiang Li

Lei Tao

Youxue Ding

Lan Liu

Yong Zhou

Chuncui Jia

Chunming Rao

Junzhi Wang

Affiliations

Soon will be listed here.

Abstract

Recombinant human interferon α2b (rhIFNα2b) is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C. The current identification test for rhIFNα2b is complex. In this study, an anti-rhIFNα2b nanobody was discovered and used for the development of a rapid lateral flow strip for the identification of rhIFNα2b. RhIFNα2b was used to immunize an alpaca, which established a phage nanobody library. After five steps of enrichment, the nanobody I22, which specifically bound rhIFNα2b, was isolated and inserted into the prokaryotic expression vector pET28a. After subsequent purification, the physicochemical properties of the nanobody were determined. A semiquantitative detection and rapid identification assay of rhIFNα2b was developed using this novel nanobody. To develop a rapid test, the nanobody I22 was coupled with a colloidal gold to produce lateral-flow test strips. The developed rhIFNα2b detection assay had a limit of detection of 1 μg/mL. The isolation of I22 and successful construction of a lateral-flow immunochromatographic test strip demonstrated the feasibility of performing ligand-binding assays on a lateral-flow test strip using recombinant protein products. The principle of this novel assay is generally applicable for the rapid testing of other commercial products, with a great potential for routine use in detecting counterfeit recombinant protein products.

Citing Articles

Transitions in Immunoassay Leading to Next-Generation Lateral Flow Assays and Future Prospects.

Fujiuchi K, Aoki N, Ohtake T, Iwashita T, Kawasaki H Biomedicines. 2024; 12(10).

PMID: 39457581 PMC: 11504701. DOI: 10.3390/biomedicines12102268.

Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.

Alexander E, Leong K J Nanobiotechnology. 2024; 22(1):661.

PMID: 39455963 PMC: 11515141. DOI: 10.1186/s12951-024-02900-y.

Development of nanobodies against the coat protein of maize chlorotic mottle virus.

Njeru F, Zwaenepoel O, Haesaert G, Misinzo G, De Jonghe K, Gettemans J FEBS Open Bio. 2024; 14(10):1746-1757.

PMID: 39168939 PMC: 11452299. DOI: 10.1002/2211-5463.13882.

Unleashing the power of colloidal gold immunochromatographic assays for plant virus diagnostics.

Ghorbani A, Astaraki S, Rostami M, Pakdel A MethodsX. 2023; 12:102498.

PMID: 38089155 PMC: 10714363. DOI: 10.1016/j.mex.2023.102498.

NANOBODIES®: A Review of Diagnostic and Therapeutic Applications.

Jin B, Odongo S, Radwanska M, Magez S Int J Mol Sci. 2023; 24(6).

PMID: 36983063 PMC: 10057852. DOI: 10.3390/ijms24065994.

References

Stevens R . Design of high-throughput methods of protein production for structural biology. Structure. 2000; 8(9):R177-85. DOI: 10.1016/s0969-2126(00)00193-3. View

Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S . Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002; 98(3):456-62. DOI: 10.1002/ijc.10212. View

Cortez-Retamozo V, Backmann N, Senter P, Wernery U, De Baetselier P, Muyldermans S . Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64(8):2853-7. DOI: 10.1158/0008-5472.can-03-3935. View

Liu J, Zabetakis D, Goldman E, Anderson G . Selection and characterization of single domain antibodies against human CD20. Mol Immunol. 2016; 78:146-154. DOI: 10.1016/j.molimm.2016.09.013. View

Kunz P, Zinner K, Mucke N, Bartoschik T, Muyldermans S, Hoheisel J . The structural basis of nanobody unfolding reversibility and thermoresistance. Sci Rep. 2018; 8(1):7934. PMC: 5962586. DOI: 10.1038/s41598-018-26338-z. View

Li C, Tang Z, Hu Z, Wang Y, Yang X, Mo F . Natural Single-Domain Antibody-Nanobody: A Novel Concept in the Antibody Field. J Biomed Nanotechnol. 2018; 14(1):1-19. DOI: 10.1166/jbn.2018.2463. View

Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A . Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol. 2012; 30(2):205-9. DOI: 10.1016/j.nbt.2012.09.002. View

Terpe K . Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2003; 60(5):523-33. DOI: 10.1007/s00253-002-1158-6. View

Isaacs A, Lindenmann J . Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267. J Immunol. 2015; 195(5):1911-20. View

10.

Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken L . Single-domain antibody fragments with high conformational stability. Protein Sci. 2002; 11(3):500-15. PMC: 2373476. DOI: 10.1110/ps.34602. View

11.

Aujame L, Geoffroy F, Sodoyer R . High affinity human antibodies by phage display. Hum Antibodies. 1997; 8(4):155-68. View

12.

Waugh D . Making the most of affinity tags. Trends Biotechnol. 2005; 23(6):316-20. DOI: 10.1016/j.tibtech.2005.03.012. View

13.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

14.

van der Linden R, Frenken L, de Geus B, Harmsen M, Ruuls R, Stok W . Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta. 1999; 1431(1):37-46. DOI: 10.1016/s0167-4838(99)00030-8. View

15.

Kobayashi N, Karibe T, Goto J . Dissociation-independent selection of high-affinity anti-hapten phage antibodies using cleavable biotin-conjugated haptens. Anal Biochem. 2005; 347(2):287-96. DOI: 10.1016/j.ab.2005.09.016. View

16.

Yamagata M, Sanes J . Reporter-nanobody fusions (RANbodies) as versatile, small, sensitive immunohistochemical reagents. Proc Natl Acad Sci U S A. 2018; 115(9):2126-2131. PMC: 5834735. DOI: 10.1073/pnas.1722491115. View

17.

Mitchell L, Colwell L . Comparative analysis of nanobody sequence and structure data. Proteins. 2018; 86(7):697-706. PMC: 6033041. DOI: 10.1002/prot.25497. View

18.

Hemmer C, Djennane S, Ackerer L, Hleibieh K, Marmonier A, Gersch S . Nanobody-mediated resistance to Grapevine fanleaf virus in plants. Plant Biotechnol J. 2017; 16(2):660-671. PMC: 5787842. DOI: 10.1111/pbi.12819. View

19.

Zhu M, Gong X, Hu Y, Ou W, Wan Y . Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. J Transl Med. 2014; 12:352. PMC: 4274719. DOI: 10.1186/s12967-014-0352-5. View

20.

Schotte P, Dewerte I, De Groeve M, De Keyser S, De Brabandere V, Stanssens P . Pichia pastoris Mut(S) strains are prone to misincorporation of O-methyl-L-homoserine at methionine residues when methanol is used as the sole carbon source. Microb Cell Fact. 2016; 15:98. PMC: 4897801. DOI: 10.1186/s12934-016-0499-2. View